Home › Funds › RA CAPITAL MANAGEMENT, L.P. › FDMT

RA CAPITAL MANAGEMENT, L.P. position in FDMT

4D MOLECULAR THERAPEUTICS IN · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 5,049,779 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$67.2M, representing 0.58% of its reported portfolio and ranking #34 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed FDMT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)5.05M sh
Reported value held$67.16M
Portfolio Weight0.58%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s FDMT position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in FDMT in Q3 2023 at 4,163,211 shares (US$53.0M). The position peaked in Q1 2024 at 5,051,511 shares, worth US$160.9M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 5,049,779 shares valued at US$67.2M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.16M $53.00M New
Q4 2023 4.16M $84.35M Hold
Q1 2024 5.05M $160.94M Add
Q2 2024 5.10M $107.01M Add
Q3 2024 5.10M $55.11M Hold
Q4 2024 4.56M $25.42M Reduce
Q1 2025 4.56M $14.74M Hold
Q2 2025 4.56M $16.93M Hold
Q3 2025 4.56M $39.65M Hold
Q4 2025 5.65M $42.40M Add
Q1 2026 5.05M $47.01M Reduce
Q2 2026 5.05M $67.16M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About FDMT and 13F data

FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M), Trails Edge Capital Partners, LP (US$29.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding FDMT

All FDMT fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held FDMT?

RA CAPITAL MANAGEMENT, L.P. has disclosed FDMT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in FDMT?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 5.05M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $67.16M, representing 0.58% of its reported portfolio and ranking #34.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling FDMT?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in FDMT. The position peaked in Q1 2024 at 5.05M shares.

Which other funds hold FDMT?

Other major institutional holders of FDMT include Novo Holdings A/S, BVF INC/IL, Trails Edge Capital Partners, LP, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.